GC
RGLS

Guggenheim Capital’s Regulus Therapeutics RGLS Stock Holding History

Guggenheim Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-217
Closed -$19K – 2559
2018
Q1 		$19K Buy
217
+1
+0.5% +$134 ﹤0.01% 2746
2017
Q4 		$27K Sell
216
-26
-11% -$3.29K ﹤0.01% 2660
2017
Q3 		$36K Buy
+242
New +$30.4K ﹤0.01% 2716
2015
Q2 		– Sell
-1,830
Closed -$3.72M – 3084
2015
Q1 		$3.72M Buy
1,830
+267
+17% +$580K 0.01% 1331
2014
Q4 		$3.01M Buy
+1,563
New +$2.78M 0.01% 1438

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Guggenheim Capital's RGLS Position: Q2 2018 in Review

Guggenheim Capital sold out of Regulus Therapeutics (RGLS) in Q2 2018, closing a stake of 217 shares — an estimated $19K sold.

Guggenheim Capital first reported a position in RGLS in Q4 2014 and held it in 5 quarters. The position peaked at $3.72M in Q1 2015. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2018.

  • Guggenheim Capital reported no remaining Regulus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 217 Regulus Therapeutics shares in Q2 2018, an estimated $19K.
  • Guggenheim Capital first reported a position in Regulus Therapeutics in Q4 2014 and held it in 5 quarters.
  • Guggenheim Capital's Regulus Therapeutics position peaked at $3.72M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.